The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously ...

Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary - As cancer rates climb ...

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver ...

Disease-free and overall survival were comparable between paclitaxel- and cisplatin-based heated chemotherapy regimens in ...

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...